

1 **SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity**

2  
3 William S. Phipps, MD<sup>1,\*</sup>  
4 Jeffrey A. SoRelle, MD<sup>1,\*</sup>  
5 Quan-Zhen Li, MD, PhD<sup>2,3\*</sup>  
6 Lenin Mahimainathan, PhD, MB(ASCP)<sup>1</sup>  
7 Ellen Araj, MD<sup>1</sup>  
8 John Markantonis, DO<sup>1</sup>  
9 Chantale Lacelle, PhD<sup>1</sup>  
10 Jyoti Balani, MD<sup>1</sup>  
11 Hiren Parikh, MT(ASCP)<sup>1</sup>  
12 E. Blair Solow, MD, MSCS<sup>2</sup>  
13 David R. Karp, MD, PhD<sup>2</sup>  
14 Ravi Sarode, MD<sup>1,4</sup>  
15 Alagarraju Muthukumar<sup>1</sup>, PhD, DABCC #

16  
17 <sup>1</sup> Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas

18 <sup>2</sup> Department of Internal Medicine (Rheumatic Diseases), University of Texas Southwestern  
19 Medical Center, Dallas, Texas

20 <sup>3</sup> Department of Immunology, Microarray Core Facility, University of Texas Southwestern  
21 Medical Center, Dallas, Texas

22 <sup>4</sup> Department of Internal Medicine (Hematology/Oncology), University of Texas Southwestern  
23 Medical Center, Dallas, Texas

24  
25 \*These authors contributed equally to this work. Author order was determined by chronological  
26 order of becoming involved with the project.

27  
28 #Send correspondence to:

29 Alagarraju Muthukumar, PhD  
30 Department of Pathology  
31 5323 Harry Hines Blvd  
32 Dallas, TX 75390  
33 Tel:214-645-5103  
34 Email: Alagarraju.Muthukumar@UTSouthwestern.edu

35  
36 Running Title: SARS-CoV-2 Antibody responses and COVID-19 severity

37 Key words: COVID-19, Coronavirus Disease 2019, SARS-CoV-2, Clinical Validation, EUA

38  
39 Commercial Interest Disclosure:

40  
41 The following authors have no interests to disclose: WP, JS, QL, LM, EA, JM, CL, JB, HP, EBS,  
42 DK, RS, AM

43 The following authors have these interests to disclose: None

44 **ABSTRACT**

45 **Background:** Initial reports indicate adequate performance of some serological-based SARS-  
46 CoV-2 assays. However, additional studies are required to facilitate interpretation of results,  
47 including how antibody levels impact immunity and disease course.

48 **Methods:** In this study, a total of 968 subjects were tested for IgG antibodies reactive to SARS-  
49 CoV-2. We confirmed analytic specificity using 656 plasma samples from healthy donors, 49  
50 sera from patients with rheumatic disease, and 90 specimens from individuals positive for PCR-  
51 based respiratory viral panel. One-hundred seventy-three cases of confirmed or suspected SARS-  
52 CoV-2 were tested for IgG. A subgroup of 37 SARS-CoV-2 PCR-positive cases was tested for  
53 nucleocapsid-specific IgM antibody using an in-house developed microarray method. Antibody  
54 levels were compared between disease severity groups.

55 **Results:** All specificity specimens were negative for SARS-CoV-2 IgG antibodies (0/656, 0%).  
56 Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid  
57 factor, or cases with previous diagnosis of viral infection including human coronavirus. Positive  
58 agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from  
59 symptom onset, with less than 100% sensitivity attributable to a case with severe  
60 immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3  
61 days from symptom onset. No association was observed between mild and severe disease course  
62 with respect to IgG and IgM levels.

63 **Conclusions:** The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse cross-  
64 reactivity. Index values of IgG and IgM antibodies did not predict disease severity in our patient  
65 population.

## 66 INTRODUCTION

67 As the COVID-19 global pandemic (1) continues, a major priority is the application of  
68 serological testing to determine the scale and rate of exposures. The COVID-19 pathogen,  
69 SARS-CoV-2 (2), is an enveloped, positive-sense, single-stranded RNA Betacoronavirus with a  
70 ~30 kilobase genome. The molecular detection of SARS-CoV-2 is based on targeting the viral  
71 genome (e.g., Orf1a/b, E, S, N genes) by polymerase chain reaction (PCR) (3–7), and is currently  
72 the gold standard to diagnose acute infection (3). Cellular and humoral immunity resolve the  
73 infection, which can be detected by the formation of antibodies specific for the virus.

74 Various serological assays have recently acquired FDA’s emergency use authority (EUA) for  
75 SARS-CoV-2 antibody testing in COVID-19 patients, but the interpretation of antibody data and  
76 their clinical significance remains challenging. Understanding the time course of antibody  
77 response and potential reasons for apparent failure of seroconversion are essential. Further,  
78 before assessing whether specific antibodies ameliorate SARS-CoV-2 infection or prevent  
79 reinfection, confidence in the analytical specificity of the test is required. Antibody assays are  
80 frequently susceptible to non-specific reactivity leading to false positives. This can have  
81 dramatic effects when the incidence of exposure is low. Thus, a high positive predictive value  
82 gained from minimal cross reactivity towards other pathogen or autoimmune-associated  
83 antibodies is critical.

84 Long, et al. have described a variable antiviral IgM and IgG immune response to SARS-CoV-2  
85 infection in a Chinese population (8), in which seroconversion in a group of 285 patients from 3  
86 hospitals, showed IgG positivity for all cases beyond 17-19 days. Bryan, et al. demonstrated  
87 timing of seroconversion for an Idaho population (9). Additional studies are lacking for the U.S.

88 population. The goals of this study were to ascertain key performance metrics of analytical  
89 specificity and cross reactivity for a SARS-CoV-2 IgG serological assay, perform a detailed  
90 cross-sectional and serial assessment of IgG and IgM antibody responses in suspected COVID-  
91 19 patients, and determine their relation to disease severity.

92

## 93 **MATERIALS AND METHODS**

94 ***Patient samples.*** This study was approved by the UT Southwestern Institutional Review Board.

95 A total of 968 individuals (996 total specimens) were included in this study, including 656  
96 healthy controls, 29 patients with systemic lupus erythematosus, 20 with rheumatoid arthritis, 90  
97 with previous positive respiratory viral PCR panel, and 173 confirmed or suspected cases of  
98 COVID-19 (**Fig. 1**).

99 ***SARS-CoV-2 IgG Testing.*** SARS-CoV-2 IgG (Abbott 06R86) testing was performed on the  
100 Abbott ARCHITECT i2000SR in accordance with manufacturer's specifications. The test is a  
101 chemiluminescent microparticle immunoassay (CMIA) for qualitative detection of IgG  
102 antibodies against SARS-CoV-2 nucleocapsid protein (NCP) in human serum and plasma.  
103 Strength of response in relative light units (RLU) reflects quantity of IgG present, and is  
104 compared to a calibrator to determine the calculated Index (Specimen/Calibrator, S/C) for a  
105 sample (with positive at 1.4 or greater).

106 ***SARS-CoV-2 IgM testing.*** IgM antibody reactivity against SARS-CoV-2 NCP was measured  
107 using a laboratory developed protein microarray as described previously (10). Briefly, NCP  
108 expressed in baculovirus insect cells (Sino Biological) and in *E. Coli* (Creative Diagnostics)  
109 along with control proteins (human IgM and anti-human IgM) were printed onto nitrocellulose

110 membrane coated slides (Grace Bio) in sextuple using a Nanoplotter NP2.1 microarray Inkjet  
111 printer (Gesim, Germany). Patient serum samples were diluted 1:100 and incubated with the  
112 antigens on the array and the IgM antibody specificities detected with cy5-conjugated anti-  
113 human IgM (1:1000, Jackson ImmunoResearch). The array was scanned using Genepix 4400A  
114 scanner (Molecular Device) at wavelength 635 nm. The resulting images were analyzed using  
115 Genepix Pro 7.0 software (Molecular Devices). The median of the signal intensity for each spot  
116 was calculated and the local background around the spot subtracted, and data obtained from  
117 sextuple spots were averaged. The background subtracted signal intensity was normalized to the  
118 average intensity of the total human IgM (internal positive control) to generate normalized signal  
119 intensity (NSI). Samples with  $NSI \geq 25$  were considered positive for IgM. The NSI of NCP IgM  
120 was used to generate heat maps using Cluster and Treeview software  
121 (<http://bonsai.hgc.jp/~mdehoon/software/cluster/index.html>).

122 **Analytical specificity.** Specificity was evaluated using 240 banked plasma samples collected  
123 prior to the COVID-19 pandemic (blood donors September through November 2019), and an  
124 additional 416 healthy donors without recent illness collected from March to April, 2020.

125 **Cross-reactivity studies.** Cross reactivity specimens were collected by cross referencing banked  
126 serum in the HLA lab (January 1, 2015- September 30, 2019) with patients who had previously  
127 tested positive for cytomegalovirus (CMV IgG), influenza A/B, RSV, or an endemic  
128 Coronavirus (NL63, 229E, OC43 or HKU1) by viral molecular tests. As the patients may have  
129 been immunosuppressed, we included only those specimens having normal or high levels of total  
130 IgG (measured alongside SARS-CoV-2) with no infusion of intravenous immunoglobulin in the  
131 preceding 3 months. Interfering substance specimens came from a collection of residual serum  
132 from a study of systemic lupus erythematosus patients that were positive for ANA and other

133 autoantibodies (n=29 collected 2004-2007). Patient samples strongly positive for rheumatoid  
134 factor (n=20 collected 2011-2014) were also evaluated.

135 **Agreement with PCR-based testing.** Agreement with PCR-based molecular testing was  
136 determined using 173 plasma samples collected (147 lithium heparin, 13 EDTA, 12 sodium  
137 citrate, and 1 sodium fluoride anticoagulants) from suspected COVID-19 cases with prior or  
138 same-day PCR-based nasopharyngeal swab testing on the m2000 Abbott RealTime SARS Cov-2  
139 assay or the Abbott ID NOW™ COVID-19 assay. Patient charts were reviewed to determine  
140 time between symptom onset (fever, respiratory symptoms, or gastrointestinal complaints) and  
141 severity of condition (whether or not intensive care was required). A subgroup of 37 PCR-  
142 positive cases (17 IgG positive, 20 IgG negative) were additionally evaluated for SARS-CoV-2  
143 IgM.

144 **Serial Patient Monitoring.** For 15 PCR-positive cases, two to six serial measurements were  
145 performed using available residual plasma samples. IgG levels and seroconversion based on  
146 calculated Index (S/C) were tracked over time.

147 **Statistics.** The calculated Index (Specimen/Calibrator, S/C, IgG level) was provided by the  
148 instrument. When multiple values of IgG S/C were compared, a mean and standard deviation  
149 were calculated. Student's t-test was used to compare two groups of non-parametrically  
150 distributed data and p-value <0.05 was considered significant.

151

## 152 **RESULTS**

153 **Analytical Specificity.** The SARS-CoV-2 IgG assay was calibrated followed by an imprecision  
154 study performed over a period of 5 consecutive days and was found to be acceptable. Analytical

155 specificity of the assay was evaluated with samples from healthy blood donors and none of these  
156 samples (0/656) were positive for virus-specific IgG (**Table 1**) and the mean index value was  
157 0.04, well below the cut-off of 1.4 for a positive index value.

158 ***Cross-reactivity studies.*** To determine whether antibodies formed in response to viral respiratory  
159 infections may cross-react with the SARS-CoV-2 antigen (NCP) on the assay's paramagnetic  
160 beads, we included samples of patients who had tested positive on a molecular based respiratory  
161 viral panel test (**Table 1**). We excluded any patients treated with intravenous immunoglobulin in  
162 the last 3 months. As some patients were post-transplant and on immunosuppression  
163 medications, we quantitated total IgG and excluded any samples with hypogammaglobulinemia  
164 (low IgG) to reduce false negative results. We tested 23 CMV IgG positive samples and none  
165 were COVID-19 IgG positive (0/23, 0%). No cases associated with prior Flu A+ (n=8), Flu B+  
166 (n=7), RSV+ (n=6), or all 4 types of human coronavirus (n=47) demonstrated cross-reactivity  
167 (0/90, 0%).

168 Likewise, we tested 29 samples from lupus patients that were positive for multiple  
169 autoantibodies (100% ANA, 62% anti-dsDNA, 75% anti-U1RNP, 55% anti-Sm, 34% anti-Ro52,  
170 and 24% anti-La) and an additional 20 samples from rheumatoid arthritis patients positive for  
171 rheumatoid factor (85% were also anti-CCP positive). None of these sera with clinically  
172 significant levels of autoantibodies produced a positive antiviral IgG test result (0/49, 0%)  
173 (**Table 2**). Highest mean of S/C ratio observed was 0.05 for human coronaviruses and 0.08 for  
174 rheumatic diseases.

175 ***Cross-Sectional data for SARS-CoV-2 IgG and IgM.*** Of 173 suspected COVID-19 cases, 76  
176 were confirmed positive by PCR methods. Overall, 29 of 76 (38%) tested positive for SARS-

177 CoV-2 IgG. The time course of symptom onset revealed increasing IgG positivity rates (**Table 3**)  
178 from <3 days (1/15, 7%), to 3-7 days (8/27, 30%), 5-15 (5/15, 33%), and being the highest after  
179 14 days (5/6, 83%). IgG positivity was high (10/13, 77%) for patients with indeterminate time  
180 from symptom onset. IgM testing (**Fig. 2**) performed on 37 PCR positive specimens showed  
181 positivity in 9 of 17 (53%) IgG positive cases and, interestingly, in 7 of 20 (35%) IgG negative  
182 samples. IgM positivity occurred at larger proportion for <3 days (3/6, 50%) compared to IgG,  
183 but at similar rates overall at days 3-7 (4/11, 36%), days 8-13 (4/11, 36%), and after 2 weeks  
184 (4/5, 80%). IgM positivity was low (1/4, 25%) for patients with indeterminate time from  
185 symptom onset.

186 SARS-CoV-2 IgG antibody results agreed with the PCR negative samples for 96 of 97 (99%) of  
187 cases, including 55 instances of patients with new or acute-on-chronic symptoms suspicious for  
188 COVID-19 and with known time of onset.

189 ***Disease severity and IgG and IgM value.*** We hypothesized that a more severe disease course  
190 was related to an increased immune response, which may result in a higher level of SARS-CoV-  
191 2 IgG antibody reactivity. Cytokine storm has been implicated as a potential life-threatening  
192 event in SARS-CoV-2 infection, and this would activate many aspects of the immune system  
193 including the humoral antibody response. We compared IgG levels from all SARS-CoV-2 PCR-  
194 positive patients who had a mild/ moderate disease course to those who had severe disease  
195 (admitted to the ICU), and there was no difference in IgG antibody levels between the two  
196 groups (**Fig 3A**).

197 Next, we assessed the impact of timing of collection on the antibody response by comparing the  
198 number of days since symptom onset between mild/ moderate and severe disease status (**Fig.**



199 **3B**). Severely affected patients had higher IgG antibody levels measured at a later time compared  
200 to mild cases ( $p < 0.05$ ). Similarly, higher IgM levels were observed in severely affected patients  
201 (**Fig. 3C, D**). It is possible that the course of IgG levels was qualitatively different in severe  
202 patients, so data from serially collected IgG samples was plotted against day of symptom onset  
203 (**Fig. 4**). Severely affected patients were tracked longer, because they were hospitalized longer,  
204 but a similar early increase in antibody titers was observed in mild/moderately affected patients  
205 when compared to severely affected patients. Interestingly, one patient was seronegative even on  
206 day 28, but this was attributed to immunosuppression to prevent cardiac transplant rejection.

207 ***Serial Patient Monitoring and Seroconversion.*** Thirty-eight samples were available from 13  
208 patients with known date of symptom onset (Fig. 3C) and 4 samples from 2 patients with  
209 indeterminate date of symptom onset. Within this group, 77% (10/13) became IgG positive,  
210 including specifically 0% (0/8) for less than 3 days post symptom onset, 33% (3/9) at 3-7 days  
211 post-symptom onset, 86% (6/7) at 8-13 days post-symptom onset, and 91% (10/11) at more than  
212 14 days (**Figure 4**). For those where seroconversion was not observed, samples were only  
213 available for less than 7 days from symptom onset for 2 cases or patient was subject to  
214 significant immunosuppression. For the two cases with indeterminate date of symptom onset,  
215 one demonstrated seroconversion between samples 11 days apart. The second case did not  
216 demonstrate seroconversion over 9 days.

## 217 **DISCUSSION**

218 Here we confirmed the high specificity reported by the manufacturer for a SARS-CoV-2 IgG  
219 serological assay, using comparatively larger groups for certain rheumatological conditions and  
220 infections. Notably, CMV IgG did not cause assay interference despite potential false positivity

221 reported by the manufacturer. Rheumatoid factor is an anti-human antibody (IgM or IgG) that, if  
222 complexed with other human immunoglobulins, could falsely increase positivity of an assay.  
223 However, we observed no interference by rheumatoid factor in 20 samples. Testing 47 samples  
224 with prior endemic coronavirus infection yielded no false positives. Negative agreement between  
225 IgG and PCR indicated only one case testing IgG positive despite negative PCR testing. This  
226 initial PCR result was later determined to be a false negative based on evaluation using an  
227 alternative molecular platform. Positive agreement with PCR was lower in the early stages of  
228 infection, increasing with time from symptom onset, yet not as quickly compared to the  
229 manufacturer's report.

230 Overall, our results largely corroborate and add to the findings by Bryan, et al. (9) who  
231 evaluating the same platform. The study showed high specificity in testing 1020 specimens  
232 submitted for HSV Western blot serology from before the COVID-19 pandemic. As such,  
233 specificity and cross reactivity were not specifically addressed in the setting of underlying  
234 rheumatologic disease or previous endemic coronavirus. A possible difference between our  
235 findings was sensitivity after 14 days of symptoms. In our study, a single negative case attributed  
236 to a patient with marked immunosuppression resulted in reduced sensitivity beyond 14 days. An  
237 unknown factor in similar studies are the number of cases included with severe underlying  
238 immunosuppression. For instance, a recent publication by Long, et al. also indicated 100% IgG  
239 positivity at 17-19 days. This latter study utilized a different assay and focused on a population  
240 in China, and was thus not as comparable. However, the same question persists regarding the  
241 makeup of comorbidities in the test population and highlights that discrepancies may arise in  
242 antibody response when comparing serology in unequal groups. Nonetheless, within our serial  
243 testing group, given the higher number of cases beyond 14 days, we did encounter sensitivity of

244 91% (10/11), which was closer to the findings of Bryan and Long. As with Bryan, et al., we have  
245 noticed alternative cutoff values for IgG level could be utilized with potentially beneficial  
246 diagnostic effects. As an example, lowering the cutoff by half (to 0.7) would capture an  
247 additional four cases with mid-range days from symptom onset (5 to 11) without any loss in  
248 specificity based the PCR result.

249 Long, et al. had reported a counter-intuitive peak of IgM positivity (20-22 days) later than for  
250 IgG positivity (17-19 days). IgM responses usually peak within the first week after infection and  
251 before IgG class switching. When early in infection, IgG may not yet be positive. When we  
252 tested samples for IgM reactivity, seven IgG negative cases were positive for IgM. These  
253 samples were positive for IgM earlier than IgG, with onset ranging from 0 to 11 days from  
254 symptom onset. This increased the sensitivity by 35% within the IgG negative samples tested  
255 (7/20) and improved diagnostic utility by 9% overall (7/76).

256 As described, we segregated our IgG and IgM results based on severity (ICU care versus no ICU  
257 care). Long, et al. indicated that a severe disease course resulted in a high IgG level during the  
258 second week of disease that becomes indistinguishable from milder cases after 14 days (9). We  
259 did not observe such a difference using a different CMIA method. This could be due to fewer  
260 patient samples, but the significance of their finding was very strong, which indicates it should  
261 have replicated were it a real phenomenon. IgM levels in our study showed no significant  
262 difference when analyzed by disease severity. Thus, antibody levels themselves do not appear to  
263 reflect disease severity.

264 A major hurdle to validation was access to patients after a sufficient time period of infection  
265 because most patients presented before 14 days from symptom onset. Limited resources and self-

266 quarantine measures have impaired repeated testing for serial testing at a later date.  
267 Consequently, less data on mild and moderate patients existed compared to patients admitted to  
268 the ICU. We do however have the advantage of reviewing medical charts to find examples of  
269 false negative by PCR and false negative by serology. These examples indicate that molecular  
270 and serologic testing have complementary roles in tracking exposure to SARS-CoV-2. Our data  
271 does not provide information on how long IgG stays positive in the long term or whether it  
272 specifically confers immunity.

## 273 **CONCLUSIONS**

274 As communities continue to grapple with the COVID-19 pandemic, reliable measures of  
275 previous exposure and immunity are essential. Several platforms are now coming into broader  
276 clinical use, providing a window into the SARS-CoV-2 antibody response. Widespread efforts to  
277 track SARS-CoV-2 patients for antibody development will clarify expectations for when testing  
278 should return positive, situations in which seroconversion may fail, and what the antibody  
279 response can tell us in patients with active infections.

## 280 **ACKNOWLEDGMENTS**

281 We would like to thank Clements University Hospital Core lab staff, especially Brittany Diaz,  
282 Sylynn Garza and Charles Alexis for serology testing and archiving of all the samples related to  
283 this study. We also acknowledge Carter Blood Care (Bedford, TX) for their archived patient  
284 samples for specificity studies and the Human Leukocyte Antigen lab at UT Southwestern for  
285 their help in retrieving banked serum samples for cross-reactivity studies, as well as Dr. Ashley  
286 Young for aid in chart review.

287 **REFERENCES**

- 288 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-  
289 L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X,  
290 Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-  
291 F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable  
292 bat origin. *Nature* 579:270–273.
- 293 2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.  
294 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying  
295 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 5:536–544.
- 296 3. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel For  
297 Emergency Use Only Instructions for Use. Centers for Disease Control and Prevention,  
298 Atlanta, GA
- 299 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink  
300 S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink  
301 S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H,  
302 Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-  
303 nCoV) by real-time RT-PCR. *Eurosurveillance* 25.
- 304 5. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV  
305 in humans. World Health Organization. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance)  
306 [coronavirus-2019/technical-guidance/laboratory-guidance](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance). Accessed March 31, 2020.

- 307 6. Chan JF-W, Yip CC-Y, To KK-W, Tang TH-C, Wong SC-Y, Leung K-H, Fung AY-F,  
308 Ng AC-K, Zou Z, Tsoi H-W, Choi GK-Y, Tam AR, Cheng VC-C, Chan K-H, Tsang OT-  
309 Y, Yuen K-Y. 2020. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly  
310 Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR  
311 Assay Validated In Vitro and with Clinical Specimens. *J Clin Microbiol* 58.
- 312 7. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC,  
313 Yang P, Wang Q, Peiris M, Poon LLM. 2020. Molecular Diagnosis of a Novel  
314 Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* 66:549–555.
- 315 8. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai  
316 X-F, Wang D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L,  
317 Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-  
318 B, Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu  
319 C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J,  
320 Li Q, Hu J-L, Chen J, Huang A-L. 2020. Antibody responses to SARS-CoV-2 in patients  
321 with COVID-19. *Nat Med*.
- 322 9. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR,  
323 Mathias PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect  
324 SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol*.
- 325 10. Zhen QL, Xie C, Wu T, Mackay M, Aranow C, Putterman C, Mohan C. 2005.  
326 Identification of autoantibody clusters that best predict lupus disease activity using  
327 glomerular proteome arrays. *J Clin Invest* 115:3428–3439.

328 **FIGURE LEGENDS**

329

330 **Figure 1. Study Cases.** Nine-hundred and sixty eight (968) unique individuals provided samples  
331 for SARS-CoV-2 IgG testing, including 15 with serial samples available. IgM testing (not  
332 shown) was performed on a group of 37 specimens (17 IgG positive, 20 IgG negative).

333

334 **Figure 2. IgM Microarray Analysis.** Array images of IgM positive and negative samples are  
335 shown (A) as well as heatmap of IgM anti-SARS-CoV-2 NCP are shown for IgG positive and  
336 negative cases of confirmed COVID-19.

337

338 **Figure 3. Antibody levels by disease severity for PCR+ subjects.** (A) SARS-CoV-2 specific  
339 IgG antibody results which were positive or negative were divided by disease severity and (B)  
340 plotted against number of days from symptom onset. (C) SARS-CoV-2 nucleocapsid specific  
341 IgM antibody results were divided by IgG positivity to demonstrate when a sample was IgM+,  
342 but IgG-. (D) IgM antibody levels were plotted against number of days from symptom onset.  
343 Middle line is the mean bars represent standard deviation. Black dots are mild/ moderate cases,  
344 while red dots represent severe cases. The red dash line in (B) represents the negative cut off  
345 level.

346

347 **Figure 4. Serial IgG measurements.** For patients with multiple samples taken, the IgG level  
348 was plotted against time from symptom onset. Black dots represent the IgG level at a specific  
349 time. Samples from the same patient are connected by either red (severe cases) or black lines  
350 (mild/ moderate cases). The dotted line indicates the threshold for a sample being positive.

351 **TABLES**

**Table 1. SARS-CoV-2 IgG Results in Healthy Donors and Cases of Previous Respiratory Viral Infection**

Sample Type	IgG, AU/mL
<b>Blood Donors</b>	
Mean±SD	0.039±0.065
Positive of n tests (%)	0/656 (0%)
<b>CMV IgG+</b>	
Mean±SD	0.07±0.067
n of Positive tests (%)	0/23 (0%)
<b>Flu A+</b>	
Mean±SD	0.13±0.19
n of Positive tests (%)	0/8 (0%)
<b>Flu B+</b>	
Mean±SD	0.11±0.17
n of Positive tests (%)	0/7 (0%)
<b>RSV+</b>	
Mean±SD	0.035±0.029
n of Positive tests (%)	0/6 (0%)
<b>Coronavirus +</b>	
Mean±SD	0.050±0.079
n of Positive tests (%)	0/47 (0%)

352

353



**Table 2. Autoantibody Interference**

Autoantibody	IgG Positivity Rate (%)
<b>Systemic lupus erythematosus (29 Patients)<sup>a</sup></b>	
ANA	0/29 (0%)
Anti-DNA	0/17 (0%)
Anti-U1RNP	0/21 (0%)
Anti-Sm	0/15 (0%)
Anti-Ro52	0/10 (0%)
Anti-La	0/7 (0%)
<b>Rheumatoid arthritis (20 Patients)<sup>b</sup></b>	
Rheumatoid factor (RF)	0/20 (0%)
Anti-CCP	0/17 (0%)

<sup>a</sup> Cases (29 total) were positive for 1 or more of the autoantibodies listed.

<sup>b</sup> All cases were RF positive, with 17/20 (85%) also anti-CCP positive.

354


355

**Table 3. SARS-CoV-2 IgG Positive Agreement by Days Post-Symptom Onset**


Time from symptom onset *	IgG Positivity Rate (%)	IgM Positivity Rate (%)
<3 days	1/15 (7%)	3/6 (50%)
3-7 days	8/27 (30%)	4/11 (36%)
8-13 days	5/15 (33%)	4/11(36%)
>14 days	5/6 (83%)	4/5 (80%)
Indeterminate	10/13 (77%)	1/4 (25%)
<b>Total</b>	<b>29/76 (38%)</b>	<b>16/37 (43%)</b>

\* For RT-PCR confirmed SARS-CoV-2 cases


356




**Figure 1. Study Cases.** Nine-hundred and sixty eight (968) unique individuals provided samples for SARS-CoV-2 IgG testing, including 15 with serial samples available. IgM testing (not shown) was performed on a group of 37 specimens (17 IgG positive, 20 IgG negative).



**Figure 2. IgM Microarray Analysis.** Array images of IgM positive and negative samples are shown (A) as well as heatmap of IgM anti-SARS-CoV-2 NCP are shown for IgG positive and negative cases of confirmed COVID-19 (B).



**Figure 3. Antibody levels by disease severity for PCR+ subjects.** (A) SARS-CoV-2 specific IgG antibody results which were positive or negative were divided by disease severity and (B) plotted against number of days from symptom onset. (C) SARS-CoV-2 nucleocapsid specific IgM antibody results were divided by IgG positivity to demonstrate when a sample was IgM+, but IgG-. (D) IgM antibody levels were plotted against number of days from symptom onset. Middle line is the mean bars represent standard deviation. Black dots are mild/moderate cases, while red dots represent severe cases. The red dash line in (B) represents the negative cut off level.



**Figure 4. Serial IgG measurements.** For patients with multiple samples taken, the IgG level was plotted against time from symptom onset. Black dots represent the IgG level at a specific time. Samples from the same patient are connected by either red (severe cases) or black lines (mild/ moderate cases). The dotted line indicates the threshold for a sample being positive.